Top Featured Companies Dominating the Cardiomyocytes Landscape
- AstraZeneca
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis
- Pfizer
- Roche
- Johnson & Johnson
- Merck & Co., Inc.
- Bayer
- Abbott Laboratories
- Bristol Myres
- Cytiva
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of cardiomyocytes is assessed at USD 5.99 billion.
The cardiomyocytes market size was over USD 5.51 billion in 2024 and is projected to reach USD 19.48 billion by 2037, witnessing around 10.2% CAGR during the forecast period i.e., between 2025-2037. The market growth is due to rising incidence of cardiovascular diseases in the world, rising investments in research and development, expanding adoption of cell therapy, and increase in healthcare expenditure and reimbursement policies.
North America industry is predicted to hold largest revenue share of 35% by 2037, as a result of presence of major Biotech and pharmaceutical companies in the region.
The major players in the market are AstraZeneca, Novartis, Pfizer, Roche, Johnson & Johnson, Merck & Co., Inc., Bayer, Abbott Laboratories, Bristol Myres, Cytiva, and others.
